What are the biological processes that stem cells go through? What are the industrial processes we need to manufacturing? What do we know about cancer stem cells? How do iPS cells fit into the picture vs. embryonic stem cells? In this episode we investigate how the science and research of stem cells is being translated into industrial cell processes to create FDA approvable, and commercializable products. Differentiation, proliferation, migration, retro-differentiation, trans-differentiation, transformation into cancer cells, the role of tumors‘ micro environments and epigenetics and all reviewed here by the field’s foremost experts.
Research has indicated that certain sarcomas come from the mesenchymal stem cells. However, expression of neural stem cells has been noted in others. Identifying and isolating mesenchymal stem cells and neural stem cells relies on finding specific proteins expressed by both types.
In this study, eight different markers representing proteins associated with these two types of stem cells were applied to the 81 tumors. Through cluster analysis, the researchers organized the data into groups showing similar patterns. Two major subgroups of pediatric sarcomas emerged
In a breakthrough, Harvard scientists have discovered that stem cells loaded with the herpes virus can be used to specifically target and kill brain tumours.
Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumour cells using cancer-killing viruses.
The work, led by Khalid Shah, an HSCI Principal Faculty member, found that trapping virus-loaded stem cells in a gel and applying them to tumours significantly improved survival in mice with glioblastoma multiforme, the most common brain tumour in human adults and also the most difficult to treat (…)
Shah and his
December 4, 2009- Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called “Twist” may be the proverbial red flag that can accurately distinguish stem cells that drive aggressive, metastatic breast cancer from other breast cancer cells.
Building on recent work suggesting that it is a relatively rare subgroup of stem cells in breast tumors that drives breast cancer, scientists have surmised that this subgroup of cells must have some very distinctive qualities and characteristics.
Stem cells could be responsible for some forms of aggressive thyroid tumors (ATC, anaplastic thyroid carcinoma). The discovery was made by a young group of biotechnologists, biologists, and doctors from the Endocrinology department of the General Hospital of the University of Palermo. In the study, published in Plos One, the researchers described a subset of tumor stem cells that were able to proliferate continuously and may be responsible for uncontrolled tumor growth. These cells are resistant to chemotherapy and explain why ATC is so highly fatal in such a short period of time. The